GSK acquires 35Pharma Inc.

GSK agreed to acquire 35Pharma Inc.. Reported deal value: $950M. Status: Announced. Sector: biopharmaceutical. Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-02-25. Figures and status may change as filings and press coverage update.

- Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases - HS235 offers potential to treat pulmonary hypertension patients while reducing the risk of bleeding and providing unique metabolic benefits compared to existing therapies - HS235 profile bolsters an emerging pipeline of products with protective benefits on metabolic and vascular function, providing scalable opportunities in GSK Respiratory, Immunology and Inflammation portfolio GSK plc today announced that it has entered an agreement to a...